GlaxoSmithKline H1N1 vaccine trial results released

GlaxoSmithKline has revealed that the results are in from the first clinical trials of its H1N1 adjuvanted vaccine.

The study showed that after one dose, candidates demonstrated a significant immunity to the virus, exceeding the immunogenicity regulations defined by international licensing authorities for a pandemic influenza vaccine.

According to the results, the adjuvanted vaccine showed that hemagglutination-inhibition titres exceeded the regulatory threshold, with a 1:40 seroconversion in more than 98 per cent of subjects who received the first dose.

Jean Stephenne, president GlaxoSmithKline biologicals, stated: “We have shared these data with both regulatory authorities and governments who are making key decisions on urgent global public healthcare at this time.”

In other GlaxoSmithKline news this week, the firm has been named by non-partisan membership organisation AARP as one for the best places for employees aged over 50 to work due to its initiatives, such as the Prime Time Partners Network.